“To See Nice(ly)”
For psychiatry, 2C9 interactions are of little clinical significance.
0% of individuals are 2C9 ultrarapid metabolizers. 5% are poor metabolizers
Conclusion: Consider checking valproic acid (VPA) levels more often if the patient is taking or stops taking enzalutamide, rifampin, or fluconazole, but don’t expect much variance from baseline. Consider avoiding paroxetine entirely.
There are no strong 2C9 inducers.
There are no strong 2C9 inhibitors.